The company’s consolidated profit excluding minority interest dropped to EGP 105.826 million in January-September from EGP 46.728 million a year earlier ...

Of the most senior full time jobs on the career ladder to chief executive, such as divisional or regional heads, only 21% are ...

GSK-sponsored survey reveals unique gaps in care and support facing patients with gynaecologic cancers: London, UK Thursday, November 14, 2024, 15:00 Hrs [IST] GSK plc announced t ...

GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...

UK pharma group posts ‘statistically significant’ trial results for treatment combined with Blenrep pulled in 2022 ...

(Alliance News) - GSK PLC on Thursday said its Blenrep drug has shown overall survival benefits in patients with relapsed or refractory multiple myeloma, the third most common type of blood cancer.

GSK reported positive results from its phase three ‘DREAMM-7’ trial on Thursday, highlighting a significant overall survival ...

GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...

GSK Pharmaceuticals India focuses on affordable general medicine access amidst premiumisation trend, discussed by managing ...

GSK added Ojjaara to its portfolio through the acquisition of Sierra in 2022. Credit: Magda Wygralak via Shutterstock. Health ...

Further boosting the pipeline, mid-stage drugs like Sanofi/Regeneron’s itepekimab, AstraZeneca’s benralizumab, Amgen Inc ...

The bottom half of the list featured Reckitt Benckiser’s Mucinex, AstraZeneca’s Breztri Aerosphere, Otsuka’s Rexulti, ...